[The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels].
Novel antihyperlipidemic micronized phenofibrate lipantil 200 M was tested for safety and efficacy (one 200 mg capsule a day for 3 months) in 27 patients having cholesterol level above 6.5 mmol/l. The effect emerged upon 1 month of administration and persisted till the end of the treatment. In combined hyperlipidemia triglycerides decreased by 45-60%, total cholesterol and LDL cholesterol by 10-12%. In isolated hyperlipidemia the latter two values appeared lower by 20-23 and 22-27%, respectively. After lipantil 200 M treatment HDL cholesterol went up by 9% in low baseline level (< 1 mmol/l) by 27%. No negative clinico-biochemical shifts were seen, while fibrinogen and uric acid reduced by 16%, apoB by 23-30%. Lipantil 200 M proved active against hyperlipidemia and is recommended for clinical practice.
Perova
N V
NV
Ozerova
I N
IN
Kalinina
A M
AM
Pavlova
L I
LI
Olfer'ev
A M
AM
Mel'kina
O E
OE
Golubev
M A
MA
Oganov
R G
RG
D000328:Adult; D000368:Aged; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D011345:Fenofibrate
Vliianie mikronizirovannogo fenofibrata na lipoproteidy plazmy krovi pri razlichnom iskhodnom urovne lipidov.